المؤلفون: Iorgulescu JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.; The Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, United States., Ruthen N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Ahn R; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States., Panagioti E; Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, United States., Neagu M; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, United States., Speranza MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Eschle BK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, United States., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, United States., Piranlioglu R; Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States., Datta M; Edwin L. Steele Laboratories for Tumor Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.; Department of Aerospace and Mechanical Engineering, University of Notre Dame, Notre Dame, IN, United States., Krishnan S; Edwin L. Steele Laboratories for Tumor Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Yates KB; The Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, United States.; Center for Cancer Research, Massachusetts General Hospital, Boston, MA, United States., Baker GJ; Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard Medical School, Boston, MA, United States.; Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, United States., Jain RK; Edwin L. Steele Laboratories for Tumor Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Suvà ML; The Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, United States.; Center for Cancer Research, Massachusetts General Hospital, Boston, MA, United States.; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Neuberg D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., White FM; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States., Chiocca EA; Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States., Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Sharpe AH; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.; The Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, United States.; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, United States., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; The Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, United States., Reardon DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

المصدر: Frontiers in immunology [Front Immunol] 2023 Dec 28; Vol. 14, pp. 1297932. Date of Electronic Publication: 2023 Dec 28 (Print Publication: 2023).

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Antigen Presentation* , Glioblastoma*, Humans ; Animals ; Mice ; Janus Kinases ; Signal Transduction ; STAT Transcription Factors ; Interferon-gamma ; Immunotherapy

المؤلفون: Gero TW; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Boston, MA 02115, USA., Heppner DE; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Boston, MA 02115, USA., Beyett TS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Boston, MA 02115, USA., To C; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Azevedo SC; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Boston, MA 02115, USA., Jang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Boston, MA 02115, USA., Bunnell T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Boston, MA 02115, USA., Feru F; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Boston, MA 02115, USA., Li Z; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Boston, MA 02115, USA., Shin BH; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston MA 02215, USA., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston MA 02215, USA., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Boston, MA 02115, USA., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Eck MJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Boston, MA 02115, USA., Scott DA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Boston, MA 02115, USA. Electronic address: davida_scott@dfci.harvard.edu.

المصدر: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2022 Jul 15; Vol. 68, pp. 128718. Date of Electronic Publication: 2022 Apr 01.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3405 (Electronic) Linking ISSN: 0960894X NLM ISO Abbreviation: Bioorg Med Chem Lett Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/metabolism , Lung Neoplasms*/metabolism, Cell Line, Tumor ; Drug Resistance, Neoplasm ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Humans ; Mutation ; Phenols ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Quinazolinones/pharmacology ; Quinazolinones/therapeutic use

المؤلفون: Ananthapadmanabhan V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Frost TC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Program in Virology, Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA., Soroko KM; Experimental Therapeutics Core at Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Knott A; Experimental Therapeutics Core at Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Magliozzi BJ; Experimental Therapeutics Core at Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Gokhale PC; Experimental Therapeutics Core at Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Tirunagaru VG; Rain Therapeutics, Newark, California, USA., Doebele RC; Rain Therapeutics, Newark, California, USA., DeCaprio JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Program in Virology, Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA.

المصدر: JCI insight [JCI Insight] 2022 Jul 08; Vol. 7 (13). Date of Electronic Publication: 2022 Jul 08.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Merkel Cell*/drug therapy , Carcinoma, Merkel Cell*/genetics , Polyomavirus Infections* , Proto-Oncogene Proteins c-mdm2*/antagonists & inhibitors , Proto-Oncogene Proteins c-mdm2*/genetics , Skin Neoplasms*/drug therapy , Skin Neoplasms*/genetics , Tumor Virus Infections*, Animals ; Antigens, Viral, Tumor/metabolism ; Humans ; Indoles/pharmacology ; Merkel cell polyomavirus ; Pyridines/pharmacology ; Pyrrolidines/pharmacology ; Tumor Suppressor Protein p53/genetics

المؤلفون: To C; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Beyett TS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Jang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; College of Pharmacy, Korea University, Sejong, Korea., Feng WW; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Bahcall M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Haikala HM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Shin BH; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Heppner DE; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Chemistry, University at Buffalo, Buffalo, NY, USA., Rana JK; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Leeper BA; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Poitras MJ; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Kobayashi Y; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan., Wahid K; Institute of Biomedicine, MediCity Research Laboratories, University of Turku, Turku, Finland., Kurppa KJ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Institute of Biomedicine, MediCity Research Laboratories, University of Turku, Turku, Finland., Gero TW; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Cameron MD; Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, USA., Ogino A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Mushajiang M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Xu C; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Zhang Y; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Scott DA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. DavidA_Scott@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. DavidA_Scott@dfci.harvard.edu., Eck MJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. michael_eck@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. michael_eck@dfci.harvard.edu., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.; Department of Medicinal Chemistry and Department of Chemistry and Systems Biology, Stanford University, Stanford, CA, USA. nathanael_gray@dfci.harvard.edu., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. pasi_janne@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. pasi_janne@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. pasi_janne@dfci.harvard.edu.

المصدر: Nature cancer [Nat Cancer] 2022 Apr; Vol. 3 (4), pp. 402-417. Date of Electronic Publication: 2022 Apr 14.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/drug therapy, Adenosine Triphosphate/therapeutic use ; ErbB Receptors/genetics ; Humans ; Mutation ; Protein Kinase Inhibitors/pharmacology

المؤلفون: Köhler J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. pasi_janne@dfci.harvard.edu jens_kohler@dfci.harvard.edu., Zhao Y; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Li J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Tiv HL; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Knott AR; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wilkens MK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Lin M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Ambrogio C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Center, University of Torino, Torino, Italy., Musteanu M; Experimental Oncology, Molecular Oncology Program, CNIO, Madrid, Spain.; Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Complutense University of Madrid, Spain., Ogino A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Choi J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Bahcall M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Bertram AA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Chambers ES; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Bhagwat SV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Manro JR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Tiu RV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Jänne PA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts. pasi_janne@dfci.harvard.edu jens_kohler@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 641-654. Date of Electronic Publication: 2021 Feb 03.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Genes, ras/*drug effects , Lung Neoplasms/*drug therapy , Oncogenes/*genetics , Protein Kinase Inhibitors/*therapeutic use, Cell Line, Tumor ; Humans ; Lung Neoplasms/pathology ; Protein Kinase Inhibitors/pharmacology

المؤلفون: Iorgulescu JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Speranza MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Eschle BK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Poitras MJ; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wilkens MK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Chhoeu C; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Knott A; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Gao Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Lim-Fat MJ; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Baker GJ; Department of Systems Biology, Harvard Medical School, Boston, Massachusetts., Bonal DM; Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, Massachusetts., Nguyen QD; Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, Massachusetts., Grant GRL; University of Glasgow Medical School, Glasgow, Scotland, United Kingdom., Ligon KL; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Sorger PK; Department of Systems Biology, Harvard Medical School, Boston, Massachusetts., Chiocca EA; Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts., Anderson AC; Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Immunology, Blavatnik Institute, Harvard Medical School and Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, Massachusetts., Kirschmeier PT; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Sharpe AH; Department of Immunology, Blavatnik Institute, Harvard Medical School and Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, Massachusetts., Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Reardon DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. david_reardon@dfci.harvard.edu.; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jan 01; Vol. 27 (1), pp. 276-287. Date of Electronic Publication: 2020 Nov 25.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Brain Edema/*drug therapy , Brain Neoplasms/*therapy , Dexamethasone/*pharmacology , Glioblastoma/*therapy , Immune Checkpoint Inhibitors/*pharmacology, Animals ; B7-H1 Antigen/antagonists & inhibitors ; Brain Edema/etiology ; Brain Neoplasms/complications ; Brain Neoplasms/genetics ; Brain Neoplasms/mortality ; Cell Line, Tumor/transplantation ; Chemoradiotherapy/methods ; Dexamethasone/therapeutic use ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Drug Interactions ; Female ; Follow-Up Studies ; Glioblastoma/complications ; Glioblastoma/genetics ; Glioblastoma/mortality ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Isocitrate Dehydrogenase/genetics ; Kaplan-Meier Estimate ; Mice ; Prognosis ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Retrospective Studies ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/immunology

المؤلفون: Morrison-Smith CD; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Knox TM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Filic I; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Eschle BK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wilkens MK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Giles F; Developmental Therapeutics Consortium, Chicago, Ilinois., Griffin A; Praxis Precision Medicines, Cambridge, Massachusetts., Brown B; Paraza Pharma Inc., Montreal, Quebec, Canada., Shapiro GI; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Zucconi BE; Department of Medicine, Division of Genetics, Brigham and Women's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Cole PA; Department of Medicine, Division of Genetics, Brigham and Women's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Lemieux ME; Bioinfo, Plantagenet, Ontario, Canada., French CA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. cfrench@bwh.harvard.edu.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2020 Jul; Vol. 19 (7), pp. 1406-1414. Date of Electronic Publication: 2020 May 05.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Benzimidazoles/*pharmacology , Carcinoma/*drug therapy , Cell Cycle Proteins/*antagonists & inhibitors , E1A-Associated p300 Protein/*antagonists & inhibitors , Gene Expression Regulation, Neoplastic/*drug effects , Neoplasm Proteins/*antagonists & inhibitors , Nuclear Proteins/*antagonists & inhibitors , Pyridones/*pharmacology , Transcription Factors/*antagonists & inhibitors, Animals ; Apoptosis ; Biomarkers, Tumor ; Carcinoma/metabolism ; Carcinoma/pathology ; Cell Cycle ; Cell Proliferation ; Humans ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays